Privigen

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Privigen
Generic name
HUMAN IMMUNOGLOBULIN G
Manufacturer
CSL Behring AG
Product type
PLASMA DERIVATIVE
SPL set ID
7e5649da-75be-4a42-8eeb-4aeba562c401
SPL ID
f9f52f8d-e858-44ed-a529-5764c0d2f01e
Version
29
Effective date
2026-05-04
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:33
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin products 1-3 , including PRIVIGEN. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. 4 PRIVIGEN does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or failure, administer PRIVIGEN at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Dosage and Administration (2.5) , Warnings and Precautions (5.2 , 5.3) ]. WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin products, including PRIVIGEN. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. ( 5.3 ) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PRIVIGEN does not contain sucrose. ( 5.2 ) For patients at risk of thrombosis, renal dysfunction or failure, administer PRIVIGEN at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. ( 5.2 , 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS IgA -deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. ( 5.1 ) Monitor renal function in patients at risk of developing renal failure. ( 5.2 ) Hyperproteinemia, hyperviscosity, and hyponatremia may occur. ( 5.4 ) Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion. ( 5.5 ) Hemolysis that is either intravascular or due to enhanced red blood cell sequestration may occur. Risk factors include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia ( 5.6 ) Elevations of blood pressure (including cases of hypertensive urgency) have been observed during/shortly following PRIVIGEN infusion. ( 5.7 ) Monitor patients for pulmonary adverse reactions (transfusion -related acute lung injury [TRALI]). ( 5.8 ) PRIVIGEN is made from human blood and may contain infectious agents. ( 5.10 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur [see Contraindications (4) ] . In case of hypersensitivity, discontinue the PRIVIGEN infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions. PRIVIGEN contains trace amounts of IgA (≤25 mcg/mL) [see Description (11) ]. Individuals with IgA deficiency can develop anti-IgA antibodies and anaphylactic reactions (including anaphylaxis and shock) after administration of blood components containing IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of PRIVIGEN. PRIVIGEN is contraindicated in patients with antibodies against IgA and a history of hypersensitivity. 5.2 Renal Dysfunction and Acute Renal Failure Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. 4 PRIVIGEN does not contain sucrose. Acute renal failure may also occur as a result of PRIVIGEN-induced hemolysis. Ensure that patients are not volume depleted and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of PRIVIGEN and at appropriate intervals thereafter. Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. 4 If renal function deteriorates, consider discontinuing PRIVIGEN. For patients judged to be at risk of developing renal dysfunction because of pre-existing renal insufficiency, or predisposition to acute renal failure (such as those with diabetes mellitus or hypovolemia, those who are obese, those who use concomitant nephrotoxic medicinal products, or those who are over 65 years of age), administer PRIVIGEN at the minimum rate of infusion practicable [see Boxed Warning , Dosage and Administration (2.5) ] . 5.3 Thrombosis Thrombosis may occur following treatment with immune globulin products 1-3 , including PRIVIGEN. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer PRIVIGEN at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Boxed Warning , Dosage and Administration (2.5) , Patient Counseling Information (17) ]. 5.4 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia Hyperproteinemia, increased serum viscosity, and hyponatremia may occur following treatment with IGIV products, including PRIVIGEN. The hyponatremia is likely to be a pseudohyponatremia, as demonstrated by a decreased calculated serum osmolality or elevated osmolar gap. It is critical to distinguish true hyponatremia from pseudohyponatremia, as treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thromboembolic events. 5 5.5 Aseptic Meningitis Syndrome (AMS) AMS may occur infrequently following treatment with PRIVIGEN [see Adverse Reactions (6) ] and other human immune globulin products. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae. 6 AMS usually begins within several hours to 2 days following IGIV treatment. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies are frequently positive with pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and with elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV [see Dosage and Administration (2.5) ] . 5.6 Hemolysis PRIVIGEN may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test (DAT) (Coombs' test) result and hemolysis. 7-9 Delayed hemolytic anemia can develop subsequent to PRIVIGEN therapy due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, has been reported. 10 Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of PRIVIGEN. The following risk factors may be associated with the development of hemolysis: high doses (e.g., ≥2 g/kg), given either as a single administration or divided over several days, and non-O blood group. 11 Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV, 12 but their role is uncertain. Hemolysis has been reported following administration of IGIV for a variety of indications, including ITP, CIDP, and PI. 9 Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above and those with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 hours and again 7 to 10 days post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform additional confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. 5.7 Hypertension Elevations of systolic blood pressure to ≥180 mm Hg and/or of diastolic blood pressure to >120 mm Hg (hypertensive urgency) have been observed during and/or shortly following infusion of PRIVIGEN. These blood pressure elevations were resolved or significantly improved within hours with either observation alone or changes in oral anti-hypertensive therapy [see Adverse Reactions (6.1) ] . Such elevations were reported more often among patients with a history of hypertension. Check patients for a history of hypertension and current antihypertensive medication use. Monitor blood pressure prior to, during, and following PRIVIGEN infusion. 5.8 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema may occur following treatment with IGIV products, including PRIVIGEN. 13 TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically appear within 1 to 6 hours following treatment. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient's serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.9 Volume Overload Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP and CIDP) in patients at increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload. 5.10 Transmissible Infectious Agents Because PRIVIGEN is made from human blood, it may carry a risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt Jakob disease [CJD] agent). The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for PRIVIGEN. Report any infection thought to be possibly transmitted by PRIVIGEN to CSL Behring Pharmacovigilance at 1-866-915-6958 . 5.11 Interference with Laboratory Tests Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 5 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following important adverse reactions are reported with IGIV: hypersensitivity, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, increased serum viscosity, hyponatremia, aseptic meningitis syndrome, hemolysis, hypertension, transfusion related acute lung injury, volume overload, and transmissible infectious agents [see Warnings and Precautions (5) ] and are described elsewhere in the prescribing information. Adverse reactions (ARs) [see Adverse Reactions (6.1) ] are defined as adverse events at least possibly related or events occurring during or within 72 hours of a PRIVIGEN infusion . The most common adverse reactions (incidence >5%) were: PI –headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. ( 6.1 ) Chronic ITP –laboratory findings consistent with hemolysis , headache, elevated body temperature, anemia, nausea, and vomiting. ( 6.1 ) CIDP – headache, asthenia, hypertension, nausea, pain in extremity, hemolysis, influenza like illness, leukopenia, and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Primary Humoral Immunodeficiency The most serious adverse reaction observed in clinical study subjects receiving PRIVIGEN for PI was hypersensitivity in one subject [see Warnings and Precautions (5.1) ] . The most common adverse reactions observed in >5% of clinical study subjects with PI were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Chronic Immune Thrombocytopenic Purpura The most serious adverse reactions observed in the premarketing clinical study subjects receiving PRIVIGEN for chronic ITP were aseptic meningitis syndrome in one subject and hemolysis in two subjects [see Warnings and Precautions (5.5 , 5.6) ] . A total of 8 subjects (14%) in the premarketing ITP study experienced hemolysis as documented from clinical laboratory data. No serious adverse reactions were observed in the postmarketing chronic ITP study. A total of 12 subjects (21%) in the postmarketing ITP study were adjudicated to have mild hemolysis as documented from clinical laboratory data [see Warnings and Precautions (5.6) ] . The most common adverse reactions observed in >5% of subjects in both clinical studies of subjects with chronic ITP were laboratory findings consistent with hemolysis (hemoglobin and hematocrit decrease without blood loss in conjunction with positive direct antiglobulin test (DAT) and elevated blood lactate dehydrogenase (LDH) and/or indirect bilirubin), headache, elevated body temperature, anemia, nausea, and vomiting. Chronic Inflammatory Demyelinating Polyneuropathy The most serious adverse reactions observed in clinical study subjects receiving PRIVIGEN for CIDP was hemolysis. The most common adverse reactions observed in >5% of subjects in both clinical studies of subjects with CIDP were headache, asthenia, hypertension, nausea, pain in extremity, hemolysis, influenza like illness, leukopenia, and rash. 6.1 Clinical Trials Experience Because different clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Treatment of Primary Humoral Immunodeficiency In a prospective, open-label, single-arm, multicenter clinical study, 80 subjects with PI (with a diagnosis of XLA or CVID) received PRIVIGEN every 3 or 4 weeks for up to 12 months [see Clinical Studies (14.1) ] . All subjects had been on regular IGIV replacement therapy for at least 6 months prior to participating in the study. Subjects ranged in age from 3 to 69; 46 (57.5%) were male and 34 (42.5%) were female. The safety analysis included all 80 subjects, 16 (20%) on the 3-week schedule and 64 (80%) on the 4-week schedule. The median dose of PRIVIGEN administered was 428 mg/kg (3-week schedule) or 441 mg/kg (4-week schedule) and ranged from 200 to 888 mg/kg. A total of 1038 infusions of PRIVIGEN were administered, 272 in the 3-week schedule and 766 in the 4-week schedule. Routine premedication was not allowed. However, subjects who experienced two consecutive infusion-related ARs that were likely to be prevented by premedication were permitted to receive antipyretics, antihistamines, NSAIDs, or antiemetic agents. During the study, 8 (10%) subjects received premedication prior to 51 (4.9%) of the 1038 infusions administered. Table 2 summarizes the most frequent ARs that occurred in >5% of subjects. Table 2. PI Pivotal Study – ARs ARs are defined as adverse events at least possibly related or events occurring during or within 72 hours of a PRIVIGEN infusion. Infections are excluded from this table. Occurring in >5% of Subjects AR Number (%) of Subjects [n=80] Number (Rate) of Infusions with AR [n=1038] Headache 36 (45.0) 100 (0.096) Fatigue 13 (16.3) 29 (0.028) Nausea 11 (13.8) 23 (0.022) Chills 9 (11.3) 15 (0.014) Vomiting 9 (11.3) 15 (0.014) Back pain 8 (10.0) 15 (0.014) Pain 7 (8.8) 14 (0.013) Elevated body temperature 7 (8.8) 12 (0.012) Diarrhea 6 (7.5) 6 (0.006) Cough 5 (6.3) 5 (0.005) Stomach discomfort 5 (6.3) 5 (0.005) Of the 192 ARs reported (including 5 serious, severe ARs described below) 91 were mild (awareness of sign, symptom or event, but easily tolerated), 81 were moderate (discomfort enough to cause interference with usual activity and may have warranted intervention), 19 were severe (incapacitating with inability to do usual activities or significantly affected clinical status, and warranted intervention), and 1 was of unknown severity. The five serious ARs (hypersensitivity, chills, fatigue, dizziness, and increased body temperature, all severe), occurred in one subject, and resulted in the subject's withdrawal from the study. Two other subjects withdrew from the study due to ARs (chills and headache in one subject; vomiting in the other). Seventy-seven of the 80 subjects enrolled in this study had a negative DAT at baseline. Of these 77 subjects, 36 (46.8%) developed a positive DAT at some time during the study. However, no subjects showed evidence of hemolytic anemia. During this study, no subjects tested positive for infection due to human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or B19 virus (B19V). An extension of the study described above was conducted in 55 adult and pediatric subjects with PI to collect additional efficacy, safety, and tolerability data. This study included 45 subjects from the pivotal study who were receiving PRIVIGEN and 10 new subjects who were receiving another IGIV product prior to enrolling in the extension study. Subjects ranged in age from 4 to 81 years; 26 (47.3%) were male and 29 (52.7%) were female. Subjects were treated with PRIVIGEN at median doses ranging from 286 to 832 mg/kg per infusion over a treatment period ranging from 1 to 27 months. Twelve (21.8%) subjects were on a 3-week treatment schedule with the number of infusions per subject ranging from 4 to 38 (median: 8 infusions); 43 (78%) subjects were on a 4-week schedule with the number of infusions ranging from 1 to 31 (median: 15 infusions). A total of 771 infusions were administered in this study. In this study, subjects who continued from the pivotal study were permitted to receive infusions of PRIVIGEN at a rate up to 12 mg/kg/min (as opposed to the maximum of 8 mg/kg/min allowed in the pivotal study) at the discretion of the investigator based on individual tolerability. Twenty-three (51%) of the 45 subjects from the pivotal study (42% of the 55 subjects in the extension study) received 265 (38%) infusions at a maximum rate greater than the recommended rate of 8 mg/kg/min [see Dosage and Administration (2.5) ] . The median of the maximum infusion rate in this subset was 12 mg/kg/min. However, because the study was not designed to compare infusion rates, no definitive conclusions regarding tolerability could be drawn for infusion rates higher than the recommended rate of 8 mg/kg/min. Table 3 summarizes the ARs that occurred in >5% of subjects. Table 3. PI Extension Study – ARs Excluding infections. Occurring in >5% of Subjects AR Number (%) of Subjects [n=55] Number (Rate) of Infusions with AR [n=771] Note: The AR rates in this study cannot be compared directly to the rates in other IGIV studies, including the original pivotal study described earlier in this section, because (1) the extension study used an enriched population and (2) the selective use of higher infusion rates at the investigators' discretion in a subset of subjects may have introduced bias. Headache 18 (32.7) 76 (0.099) Nausea 6 (10.9) 10 (0.013) Elevated body temperature 4 (7.3) 12 (0.016) Abdominal pain Includes abdominal pain, abdominal pain upper, and abdominal pain lower. 4 (7.3) 7 (0.009) Chest pain 3 (5.5) 4 (0.005) Chills 3 (5.5) 7 (0.009) Joint swelling/effusion 3 (5.5) 7 (0.009) Pain 3 (5.5) 6 (0.008) Fatigue 3 (5.5) 5 (0.006) Influenza-like illness 3 (5.5) 5 (0.006) Pharyngolaryngeal pain 3 (5.5) 4 (0.005) Urticaria 3 (5.5) 4 (0.005) Dizziness 3 (5.5) 3 (0.004) Of the 125 reported ARs, 76 were mild (did not interfere with routine activities), 40 were moderate (interfered somewhat with routine activities), and 9 were severe (impossible to perform routine activities). Three subjects experienced ARs: dyspnea and pancytopenia in one subject, a transient ischemic attack 16 days after the infusion in one subject, and mild urticaria in one subject, resulting in the subject's withdrawal from the study. Treatment of Chronic Immune Thrombocytopenic Purpura In a prospective, open-label, single-arm, multicenter premarketing clinical study, 57 subjects with chronic ITP and a platelet count of 20 × 10 9 /L or less received a total of 2 g/kg dose of PRIVIGEN administered as 1 g/kg infusions daily for 2 consecutive days [see Clinical Studies (14.2) ] . Subjects ranged in age from 15 to 69; 23 (40%) were male and 34 (60%) were female. Concomitant medications affecting platelets or other treatments for chronic ITP were not allowed. Thirty-two (56%) subjects received premedication with acetaminophen and/or an antihistamine. Table 4 summarizes the most frequent ARs that occurred in >5% of subjects with chronic ITP. Table 4. Chronic ITP Premarketing Clinical Study – ARs ARs were defined as adverse events at least possibly related or events occurring during or within 72 hours after the end of a treatment cycle [two consecutive infusions]. Occurring in >5% of Subjects AR Number (%) of Subjects [n=57] Number (Rate) of Infusions with AR [n=114] Headache 37 (64.9) 52 (0.456) Elevated body temperature 21 (36.8) 23 (0.202) Positive DAT 7 (12.3) 8 (0.070) Anemia 6 (10.5) 6 (0.053) Nausea 6 (10.5) 8 (0.070) Epistaxis 6 (10.5) 8 (0.070) Vomiting 6 (10.5) 7 (0.061) Blood bilirubin unconjugated increased 6 (10.5) 6 (0.053) Blood bilirubin conjugated increased 5 (8.8) 5 (0.044) Blood total bilirubin increased 3 (5.3) 3 (0.026) Hematocrit decreased 3 (5.3) 3 (0.026) Blood lactate dehydrogenase increased 3 (5.3) 3 (0.026) Of the 149 non-serious ARs, 103 were mild (awareness of sign, symptom or event, but easily tolerated), 37 were moderate (discomfort enough to cause interference with usual activity and may have warranted intervention), and 9 were severe (incapacitating with inability to do usual activities or significantly affected clinical status, and warranted intervention). One subject experienced a serious AR (aseptic meningitis). Eight subjects, all of whom had a positive DAT, experienced transient drug-related hemolytic reactions, which were associated with elevated bilirubin, elevated lactate dehydrogenase, and a decrease in hemoglobin level within two days after the infusion of PRIVIGEN. Two of the eight subjects were clinically anemic but did not require clinical intervention; these cases resolved uneventfully. Four other subjects with active bleeding were reported to have developed anemia without evidence of hemolysis. In this study, there was a decrease in hemoglobin after the first PRIVIGEN infusion (median decrease of 1.2 g/dL by Day 8) followed by a return to near baseline by Day 29. Fifty-six of the 57 subjects in this study had a negative DAT at baseline. Of these 56 subjects, 12 (21%) developed a positive DAT during the 29-day study period. Postmarketing Commitment Study in Chronic Immune Thrombocytopenic Purpura In a prospective, open-label, single-arm, multicenter postmarketing clinical study whose primary objective was to evaluate mechanisms of hemolysis, 57 subjects with chronic ITP and a platelet count of <30 × 10 9 /L at screening were studied following treatment with PRIVIGEN. Twenty-one (21) subjects (37%) received 1 infusion of 1 g/kg on Day 1 and 36 subjects (63%) received 2 infusions each of 1 g/kg (Day 1 and Day 3). Concomitant medications affecting platelets or other treatments for chronic ITP were not allowed. Subjects received premedication with acetaminophen and/or an antihistamine [see Clinical Studies (14.3) ] . The most frequent ARs (adverse events at least possibly related or events occurring during or within 72 hours after the end of treatment) that occurred in >5% of subjects with chronic ITP were headache (16 subjects [28%]) and pyrexia (3 subjects [5%]). No subject experienced a serious adverse reaction. Of the 23 non-serious ARs, 22 were mild (does not interfere with routine activities), 1 was moderate (interferes somewhat with routine activities), and none were severe (impossible to perform routine activities). All 57 subjects had a negative DAT at baseline. Twenty-two (38%) developed a positive DAT by Day 4, 19 of these subjects were from blood group A. Fifteen subjects were adjudicated by an independent expert committee, for presumptive/possible hemolysis, all of whom received 2 g/kg IGIV during the study [see Clinical Studies (14.3) ] . Twelve subjects (21%) were judged to have mild hemolysis. In these 12 subjects there was a median hemoglobin drop from baseline at Day 9 (nadir) of -3.0 g/dL (range -0.9 to -5.8 g/dL) with Day 9 hemoglobin values ranging from 9.9 to 13.2 g/dL and a median drop from baseline in hemogloblin of -1.2 g/dL (range -0.1 to -2.7 g/dL) at Day 29 (end of study) with hemoglobin values ranging from 11.8 to 15.8 g/dL. Ten subjects were blood group A and 2 subjects were blood group B. These hemoglobin drops were transient and were followed by recovery or partial recovery by Day 29. One subject experienced mild dyspnea between Day 9 and Day 16; 1 subject experienced mild dizziness on Day 4. No subject was judged as having experienced clinically significant intravascular hemolysis. Three of the 15 adjudicated subjects were judged not to have experienced hemolysis. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) In a prospective, open-label, single-arm, multicenter clinical study (PRIVIGEN Impact on Mobility and Autonomy [PRIMA]), 28 subjects with CIDP received a PRIVIGEN loading dose of 2 g/kg followed by PRIVIGEN maintenance doses of 1 g/kg every 3 weeks for up to 21 weeks with 3 week follow up [see Clinical Studies (14.4) ] . Administration of the loading dose occurred over 2 days and the maintenance dose over 1 day in the majority of cases. Table 5 summarizes the most frequent ARs that occurred in ≥5% of subjects with CIDP. Table 5. CIDP Clinical Study – ARs ARs were defined as adverse events at least possibly related or events occurring during or within 72 hours after IV infusion. Occurring in ≥5% of Subjects AR Number (%) of Subjects [n=28] Number (Rate) of Infusions with AR [n=259] Headache 8 (28.6) 19 (0.073) Asthenia 4 (14.3) 4 (0.015) Hypertension 4 (14.3) 6 (0.023) Nausea 3 (10.7) 3 (0.012) Pain in extremity 3 (10.7) 3 (0.012) Hemolysis 2 (7.1) 2 (0.008) Influenza like illness 2 (7.1) 2 (0.008) Leukopenia 2 (7.1) 2 (0.008) Rash 2 (7.1) 2 (0.008) Two hemolysis serious adverse reactions occurred after the start of the PRIVIGEN induction dose in subjects with non-O blood groups (A and AB). The reactions resolved after discontinuation without the need for transfusion. Four subjects, three of whom had a history of hypertension, had reversible increases in systolic blood pressure to ≥180 mm Hg during or within 1 to 4 hours following PRIVIGEN infusion. One of these subjects who had a history of untreated hypertension had a reversible increase in diastolic blood pressure from 84 mm Hg pre-infusion to 135 mm Hg at 1 hour after the end of the infusion. All were resolved or significantly improved within 1 to 6 hours with either observation alone or changes in oral anti-hypertensive therapy. A total of 71 ARs were reported: 46 were mild (does not interfere with routine activities), 23 were moderate (interferes somewhat with routine activities), and 2 were severe (impossible to perform routine activities) in intensity. In a second prospective, open-label PRIVIGEN pre-randomization phase of a multicenter, randomized, double-blind, placebo-controlled clinical study (Polyneuropathy and Treatment with Hizentra [PATH]), 207 IGIV-pretreated subjects with CIDP received a PRIVIGEN loading dose of 2 g/kg followed by up to 4 PRIVIGEN maintenance doses of 1 g/kg every three weeks for up to 13 weeks. Additionally, 60 of these subjects received PRIVIGEN rescue treatment by the same dosing regimen following CIDP relapse during the double-blind post-randomization phase [see Clinical Studies (14.4) ] . Eight subjects experienced a serious adverse reaction (acute rash cutaneous, blood pressure diastolic increased, exacerbation of CIDP [2], hypersensitivity, pulmonary embolism, respiratory failure, and migraine. The serious adverse reactions of pulmonary embolism and respiratory failure occurred in subjects with preexisting risk factors. All serious adverse reactions resolved without sequelae. Adverse reactions that occurred in >5% of subjects with CIDP were headache (33 subjects, 15.9% [rate per infusion 56/1894, 0.030]). A total of 225 ARs were reported: 160 were mild (is transient, does not usually interfere with routine activities but minimal treatment or therapeutic intervention may be required), 59 were moderate (interferes somewhat with routine activities and usually alleviated with specific intervention but poses no significant or permanent risk of harm), and 6 were severe (interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention) in intensity. 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. PRIVIGEN The following adverse reactions have been identified during postmarketing use of PRIVIGEN. This list does not include reactions already reported in clinical studies with PRIVIGEN [see Adverse Reactions (6.1) ] . Blood and lymphatic system disorders: Decreased neutrophil count Infusion reactions: Changes in blood pressure, dyspnea, tachycardia, flushing Renal: hemoglobinuria/hematuria/chromaturia, renal failure Neurological: photophobia, cerebral edema Integumentary: pruritus General In addition, the following adverse reactions have been identified and reported with the use of immune globulin products. 14 Infusion Reactions: Malaise, rigors Renal : Acute renal dysfunction/failure, osmotic nephropathy Respiratory : Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, cyanosis, hypoxemia, pulmonary edema, bronchospasm Cardiovascular: Cardiac arrest, thromboembolism, vascular collapse, hypotension Neurological: Coma, loss of consciousness, seizures, tremor Integumentary: Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis Hematologic: Pancytopenia, leukopenia Gastrointestinal: Hepatic dysfunction

adverse reactions table

<table width="75%"><caption>Table 2. PI Pivotal Study &#x2013; ARs<footnote ID="foot21">ARs are defined as adverse events at least possibly related or events occurring during or within 72 hours of a PRIVIGEN infusion. Infections are excluded from this table.</footnote> Occurring in &gt;5% of Subjects</caption><col width="50%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="25%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule">AR<footnoteRef IDREF="foot21"/></th><th styleCode="Rrule">Number (%) of Subjects [n=80]</th><th styleCode="Rrule">Number (Rate) of Infusions with AR [n=1038]</th></tr></thead><tbody><tr styleCode="botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">36 (45.0)</td><td styleCode="Rrule">100 (0.096)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">13 (16.3)</td><td styleCode="Rrule">29 (0.028)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">11 (13.8)</td><td styleCode="Rrule">23 (0.022)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Chills</td><td styleCode="Rrule">9 (11.3)</td><td styleCode="Rrule">15 (0.014)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Vomiting</td><td styleCode="Rrule">9 (11.3)</td><td styleCode="Rrule">15 (0.014)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Back pain</td><td styleCode="Rrule">8 (10.0)</td><td styleCode="Rrule">15 (0.014)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Pain</td><td styleCode="Rrule">7 (8.8)</td><td styleCode="Rrule">14 (0.013)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Elevated body temperature</td><td styleCode="Rrule">7 (8.8)</td><td styleCode="Rrule">12 (0.012)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Diarrhea</td><td styleCode="Rrule">6 (7.5)</td><td styleCode="Rrule">6 (0.006)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Cough</td><td styleCode="Rrule">5 (6.3)</td><td styleCode="Rrule">5 (0.005)</td></tr><tr><td styleCode="Lrule Rrule">Stomach discomfort</td><td styleCode="Rrule">5 (6.3)</td><td styleCode="Rrule">5 (0.005)</td></tr></tbody></table>

adverse reactions table

<table width="75%"><caption>Table 3. PI Extension Study &#x2013; ARs<footnote ID="foot31">Excluding infections.</footnote> Occurring in &gt;5% of Subjects</caption><col width="37%" align="left" valign="top"/><col width="30%" align="center" valign="top"/><col width="33%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule">AR<footnoteRef IDREF="foot31"/></th><th styleCode="Rrule">Number (%) of Subjects [n=55]</th><th styleCode="Rrule">Number (Rate) of Infusions with AR [n=771]</th></tr></thead><tfoot><tr><td colspan="3" align="left">Note: The AR rates in this study cannot be compared directly to the rates in other IGIV studies, including the original pivotal study described earlier in this section, because (1) the extension study used an enriched population and (2) the selective use of higher infusion rates at the investigators&apos; discretion in a subset of subjects may have introduced bias.</td></tr></tfoot><tbody><tr styleCode="botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">18 (32.7)</td><td styleCode="Rrule">76 (0.099)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">6 (10.9)</td><td styleCode="Rrule">10 (0.013)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Elevated body temperature</td><td styleCode="Rrule">4 (7.3)</td><td styleCode="Rrule">12 (0.016)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Abdominal pain<footnote ID="foot32">Includes abdominal pain, abdominal pain upper, and abdominal pain lower.</footnote></td><td styleCode="Rrule">4 (7.3)</td><td styleCode="Rrule">7 (0.009)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Chest pain</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">4 (0.005)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Chills</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">7 (0.009)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Joint swelling/effusion</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">7 (0.009)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Pain</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">6 (0.008)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">5 (0.006)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Influenza-like illness</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">5 (0.006)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Pharyngolaryngeal pain</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">4 (0.005)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Urticaria</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">4 (0.005)</td></tr><tr><td styleCode="Lrule Rrule">Dizziness</td><td styleCode="Rrule">3 (5.5)</td><td styleCode="Rrule">3 (0.004)</td></tr></tbody></table>

adverse reactions table

<table width="90%"><caption>Table 4. Chronic ITP Premarketing Clinical Study &#x2013; ARs<footnote ID="foot41">ARs were defined as adverse events at least possibly related or events occurring during or within 72 hours after the end of a treatment cycle [two consecutive infusions].</footnote> Occurring in &gt;5% of Subjects</caption><col width="50%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="25%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" align="center" valign="middle">AR<footnoteRef IDREF="foot41"/></th><th styleCode="Rrule">Number (%) of Subjects [n=57]</th><th styleCode="Rrule">Number (Rate) of Infusions with AR [n=114]</th></tr></thead><tbody><tr styleCode="botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">37 (64.9)</td><td styleCode="Rrule">52 (0.456)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Elevated body temperature</td><td styleCode="Rrule">21 (36.8)</td><td styleCode="Rrule">23 (0.202)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Positive DAT</td><td styleCode="Rrule">7 (12.3)</td><td styleCode="Rrule">8 (0.070)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Anemia</td><td styleCode="Rrule">6 (10.5)</td><td styleCode="Rrule">6 (0.053)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">6 (10.5)</td><td styleCode="Rrule">8 (0.070)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Epistaxis</td><td styleCode="Rrule">6 (10.5)</td><td styleCode="Rrule">8 (0.070)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Vomiting</td><td styleCode="Rrule">6 (10.5)</td><td styleCode="Rrule">7 (0.061)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Blood bilirubin unconjugated increased</td><td styleCode="Rrule">6 (10.5)</td><td styleCode="Rrule">6 (0.053)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Blood bilirubin conjugated increased</td><td styleCode="Rrule">5 (8.8)</td><td styleCode="Rrule">5 (0.044)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Blood total bilirubin increased</td><td styleCode="Rrule">3 (5.3)</td><td styleCode="Rrule">3 (0.026)</td></tr><tr styleCode="botrule"><td styleCode="Lrule Rrule">Hematocrit decreased</td><td styleCode="Rrule">3 (5.3)</td><td styleCode="Rrule">3 (0.026)</td></tr><tr><td styleCode="Lrule Rrule">Blood lactate dehydrogenase increased</td><td styleCode="Rrule">3 (5.3)</td><td styleCode="Rrule">3 (0.026)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.